Binyi Xiao

751 total citations
37 papers, 391 citations indexed

About

Binyi Xiao is a scholar working on Oncology, Pathology and Forensic Medicine and Surgery. According to data from OpenAlex, Binyi Xiao has authored 37 papers receiving a total of 391 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 18 papers in Pathology and Forensic Medicine and 12 papers in Surgery. Recurrent topics in Binyi Xiao's work include Genetic factors in colorectal cancer (18 papers), Colorectal Cancer Surgical Treatments (9 papers) and Colorectal Cancer Treatments and Studies (9 papers). Binyi Xiao is often cited by papers focused on Genetic factors in colorectal cancer (18 papers), Colorectal Cancer Surgical Treatments (9 papers) and Colorectal Cancer Treatments and Studies (9 papers). Binyi Xiao collaborates with scholars based in China, United States and Ethiopia. Binyi Xiao's co-authors include Zhizhong Pan, Peirong Ding, Jinghua Tang, Jianhong Peng, Jiang Wu, Ling-Heng Kong, Qiaoqi Sui, Qingjian Ou, Kai Han and Xiaojun Wu and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Annals of Oncology.

In The Last Decade

Binyi Xiao

36 papers receiving 387 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Binyi Xiao China	13	226	125	103	94	82	37	391
Yen‐Jung Lu Taiwan	13	186 0.8×	167 1.3×	78 0.8×	72 0.8×	111 1.4×	21	416
Federica Panebianco United States	11	183 0.8×	144 1.2×	62 0.6×	107 1.1×	73 0.9×	16	593
Xiaoli Long China	10	122 0.5×	140 1.1×	95 0.9×	56 0.6×	169 2.1×	24	388
Ye-Young Rhee South Korea	11	217 1.0×	111 0.9×	59 0.6×	153 1.6×	64 0.8×	15	352
Monica Barbolini Italy	9	254 1.1×	127 1.0×	39 0.4×	130 1.4×	117 1.4×	26	399
Linn Woelber Germany	14	150 0.7×	138 1.1×	133 1.3×	30 0.3×	90 1.1×	23	479
Shih‐Che Shen Taiwan	9	139 0.6×	105 0.8×	50 0.5×	96 1.0×	102 1.2×	21	303
Chien‐Liang Liu Taiwan	7	118 0.5×	176 1.4×	67 0.7×	82 0.9×	182 2.2×	9	429
Guo‐He Lin China	10	266 1.2×	118 0.9×	107 1.0×	28 0.3×	82 1.0×	37	427

Countries citing papers authored by Binyi Xiao

Since Specialization

Citations

This map shows the geographic impact of Binyi Xiao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Binyi Xiao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Binyi Xiao more than expected).

Fields of papers citing papers by Binyi Xiao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Binyi Xiao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Binyi Xiao. The network helps show where Binyi Xiao may publish in the future.

Co-authorship network of co-authors of Binyi Xiao

This figure shows the co-authorship network connecting the top 25 collaborators of Binyi Xiao. A scholar is included among the top collaborators of Binyi Xiao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Binyi Xiao. Binyi Xiao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hou, Zhenlin, Weiwei Xiao, Qiaoqi Sui, et al.. (2025). Neoadjuvant chemoradiotherapy plus sintilimab in pMMR/MSS rectal cancer patients with PD-L1 TPS ≥ 1% or CPS ≥ 1: an open-label, prospective, phase II study. npj Precision Oncology. 9(1). 237–237. 1 indexed citations

Chen, Hongtao, Ye Tian, Jue Zhang, et al.. (2025). Hereditary leptomeningeal transthyretin amyloidosis with heterozygous TTR mutation: a case report and literature review. Orphanet Journal of Rare Diseases. 20(1). 213–213.

Zhang, W., Qichen Chen, Fei Xiao, et al.. (2025). Development and validation of a logistic regression model for the diagnosis of colorectal cancer. Scientific Reports. 15(1). 14759–14759. 5 indexed citations

Tang, Jinghua, Jiang Wu, Yuan Li, et al.. (2024). The effects of oxaliplatin-based adjuvant chemotherapy in high-risk stage II colon cancer with mismatch repair-deficient: a retrospective study. BMC Cancer. 24(1). 164–164. 2 indexed citations

Li, Weihao, Lan Jin, Rong Yang, et al.. (2024). Chromosomal instability is associated with prognosis and efficacy of bevacizumab after resection of colorectal cancer liver metastasis. Annals of Medicine. 56(1). 2396559–2396559. 1 indexed citations

Li, Weihao, Jiayu Wang, Xiaojun Wu, et al.. (2024). MCT4 is an independent prognostic factor and affects immune cell infiltration in patients with colorectal liver oligometastases. Clinical & Translational Oncology. 27(4). 1681–1694. 1 indexed citations

Xiao, Binyi, Xuan Zhang, Dandan Li, et al.. (2023). Neoadjuvant Immunotherapy Leads to Major Response and Low Recurrence in Localized Mismatch Repair–Deficient Colorectal Cancer. Journal of the National Comprehensive Cancer Network. 21(1). 60–66.e5. 26 indexed citations

Li, Yuan, Bin Li, Rou Jiang, et al.. (2023). A novel screening method of DNA methylation biomarkers helps to improve the detection of colorectal cancer and precancerous lesions. Cancer Medicine. 12(21). 20626–20638. 9 indexed citations

Yu, Jiehai, Binyi Xiao, Jinghua Tang, et al.. (2023). Efficacy of PD-1 inhibitors for colorectal cancer and polyps in Lynch syndrome patients. European Journal of Cancer. 192. 113253–113253. 11 indexed citations

10.

Wang, Qiaoxuan, Binyi Xiao, Yong Cheng, et al.. (2022). Anti-PD-1-based immunotherapy as curative-intent treatment in dMMR/MSI-H rectal cancer: A multicentre cohort study. European Journal of Cancer. 174. 176–184. 19 indexed citations

11.

Li, Yuan, Ling-Heng Kong, Jiang Wu, et al.. (2022). DNA ploidy and stroma predicted the risk of recurrence in low-risk stage III colorectal cancer. Clinical & Translational Oncology. 25(1). 218–225. 1 indexed citations

12.

Sui, Qiaoqi, Dingxin Liu, Jiang Wu, et al.. (2021). Dickkopf 1 impairs the tumor response to PD-1 blockade by inactivating CD8+ T cells in deficient mismatch repair colorectal cancer. Journal for ImmunoTherapy of Cancer. 9(3). e001498–e001498. 43 indexed citations

13.

Deng, Yuxiang, Long Yu, Yujie Zhao, et al.. (2021). RCC1 Expression as a Prognostic Marker in Colorectal Liver Oligometastases. Pathology & Oncology Research. 27. 1610077–1610077. 8 indexed citations

14.

Peng, Jianhong, Weihao Li, Wenhua Fan, et al.. (2021). Prognostic value of a novel biomarker combining DNA ploidy and tumor burden score for initially resectable liver metastases from patients with colorectal cancer. Cancer Cell International. 21(1). 554–554. 6 indexed citations

15.

Xiao, Binyi, Jianhong Peng, Yongchun Wang, et al.. (2020). Prognostic value of tumor infiltrating lymphocytes combined with PD-L1 expression for patients with solitary colorectal cancer liver metastasis. Annals of Translational Medicine. 8(19). 1221–1221. 14 indexed citations

16.

Sui, Qiaoqi, Jian Zheng, Dingxin Liu, et al.. (2019). Dickkopf-related protein 1, a new biomarker for local immune status and poor prognosis among patients with colorectal liver Oligometastases: a retrospective study. BMC Cancer. 19(1). 1210–1210. 16 indexed citations

17.

Deng, Yuxiang, Yujie Zhao, Wenhua Fan, et al.. (2019). Preoperative AFU Is a Useful Serological Prognostic Predictor for Colorectal Liver Oligometastasis Patients Undergoing Hepatic Resection. Journal of Cancer. 10(21). 5049–5056. 2 indexed citations

18.

Xiao, Binyi, Jianhong Peng, Rongxin Zhang, et al.. (2017). Density of CD8+ lymphocytes in biopsy samples combined with the circulating lymphocyte ratio predicts pathologic complete response to chemoradiotherapy for rectal cancer. Cancer Management and Research. Volume 9. 701–708. 13 indexed citations

19.

Liu, Tianze, Wenbin Li, Wenjing Lü, et al.. (2017). RBFOX3 Promotes Tumor Growth and Progression via hTERT Signaling and Predicts a Poor Prognosis in Hepatocellular Carcinoma. Theranostics. 7(12). 3138–3154. 25 indexed citations

20.

Wang, Jingshu, Kun Zou, Feng Xu, et al.. (2017). Downregulation of NMI promotes tumor growth and predicts poor prognosis in human lung adenocarcinomas. Molecular Cancer. 16(1). 158–158. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact